Summary: Metformin, a diabetes medication, may help prevent vision loss in diabetic individuals. Research shows it reduces the risk of diabetic retinopathy, age-related macular degeneration, and glaucoma through its anti-inflammatory and antioxidative properties. Ongoing trials aim to confirm these benefits and enhance eye health management.

It is a well established fact that diabetes may cause deterioration of vision and eventually blindness through glycation of nerves and aberrant blood vessel growth in the retina through dysregulated VEGF proteins. There is evidence to strongly suggest that various eye pathologies occur less frequently with concurrent use of metformin. The article will mention adjusted hazard ratio and odds ratio. The authors adjusted variables by matching individuals with certain medical conditions to be comparing same to same in order to be able to fairly assess metformin’s effect. An odds ratio (OR) is considered less authoritative than a Relative Risk (RR) because it is based on retrospective data that is observational,however, given large populations the validity should not be dismissed

Understanding Metformin’s Role in Eye Health

Mechanisms of Action

Metformin works through multiple pathways due to its anti-inflammatory, anti-angiogenic (prevents blood vessel formation), and antioxidative properties. By activating AMP-activated protein kinase (AMPK) it interferes with the action of the mammalian target of rapamycin complex 1 (mTORC1), and blockade of mTORC1 pathway suppresses pathological retinal angiogenesis. Furthermore  Intercellular adhesion molecule-1 (ICAM-1) and Monocyte chemotactic protein-1 (MCP-1) are downregulated with metformin therefore limiting formation of aberrant blood vessels¹. Interestingly Metformin is antiangiogenic in the eye where more blood vessels is an undesirable outcome but is also pro-angiogenic where it is beneficial such as in wound healing.

Safety Profile

With a long-standing safety record, Metformin is reliable for long-term use. Common side effects are generally mild, such as gastrointestinal discomfort. Rare instances of lactic acidosis occur primarily in individuals with significant renal or hepatic impairment. It is worth noting that lactic acidosis is extremely rare, and many physicians now believe that metformin should not be held during most inpatient admissions.

Metformin’s Impact on Specific Eye Diseases

Diabetic Retinopathy (DR)

Clinical Evidence

Diabetic Retinopathy is a leading cause of blindness among diabetic patients. Studies have shown that Metformin use is associated with a reduced risk of developing DR. For instance, Metformin users had a 24% lower overall risk of retinopathy compared to non-users.

Quantifiable Data

• Adjusted Hazard Ratio (aHR) for Non-Proliferative DR (NPDR): 0.76
• aHR for Sight-Threatening DR (STDR): 0.29
• Dose-Dependent Protection: Higher cumulative doses of Metformin correlated with greater protection against DR¹.

Mechanism

Metformin inhibits vascular endothelial growth factor (VEGF) signaling, reducing abnormal blood vessel formation in the retina. It decreases inflammatory cytokines and preserves retinal architecture, mitigating the severity of DR.

Age-Related Macular Degeneration (AMD)

Clinical Evidence

AMD is a prevalent retinal disease leading to vision loss.Metformin use is linked to a decreased risk of developing AMD. A large case-control study found that Metformin users had a 7% lower odds of developing AMD (OR 0.93).

Quantifiable Data

• Odds Ratio (OR) for AMD: 0.93 (95% CI: 0.91–0.95)
• Significant Reduction in Neovascular AMD: OR 0.59¹
• Dose-Dependent Benefits: Protective effects increased with longer duration and higher cumulative doses of Metformin¹.

Mechanism

Metformin’s antioxidative properties protect retinal pigment epithelial (RPE) cells from oxidative stress—a key factor in AMD progression. By enhancing autophagy and reducing reactive oxygen species (ROS), Metformin helps maintain retinal structure and function.

Glaucoma

Clinical Evidence

Glaucoma, characterized by optic nerve damage, has been associated with Metformin use. A cohort study demonstrated a 25% reduction in the risk of developing open-angle glaucoma (OAG) among Metformin users.

Quantifiable Data

• Hazard Ratio (HR) for OAG: 0.75 (95% CI: 0.59–0.95)
• Risk Reduction per Gram of Metformin: 0.16% per 1g increase

Mechanism

Metformin may protect retinal ganglion cells by reducing inflammation and oxidative stress within the optic nerve head, slowing glaucoma progression.

Uveitis

Clinical Evidence

Uveitis, an inflammatory eye condition, may also benefit from Metformin. While initial studies found no significant protective effect, longer durations and higher cumulative doses were associated with reduced risk¹. Note the 390,000 mg of metformin is a cut-off researches used to assess which patients are considered long-term metformin users

Quantifiable Data

• Adjusted Odds Ratio (aOR) for Non-Infectious Uveitis (NIU): 0.49 for 445–729 days of use
• aOR for >390,000 mg of Metformin: 0.44

Mechanism

Metformin’s anti-inflammatory effects may reduce immune-mediated damage in uveitis, promoting ocular health.

Retinitis Pigmentosa (RP)

Clinical Evidence

Retinitis Pigmentosa, a genetic disorder causing retinal degeneration, may respond to Metformin. Preclinical studies in mice have shown prolonged photoreceptor survival with Metformin treatment.

Mechanism

Metformin aids in proper protein trafficking and reduces cellular apoptosis in photoreceptors, potentially slowing RP progression.

Strength of Evidence: Quantitative Insights

The evidence supporting Metformin’s benefits in retinal diseases is robust, especially in DR and AMD. Key findings include:

• DR Risk Reduction: Up to 76% lower risk of NPDR and 71% lower risk of STDR among Metformin users.
• AMD Protection: Approximately 7% lower odds of developing AMD, with significant reductions in neovascular AMD cases.
• Glaucoma Prevention: A 25% decrease in the risk of developing OAG.
• Uveitis Mitigation: Notable protective effects with prolonged and high-dose Metformin use.

These statistics come from large-scale studies, providing meaningful insights into Metformin’s protective roles.

Ongoing Clinical Trials

To further validate these findings, ongoing clinical trials are investigating Metformin’s efficacy in retinal diseases:

• CORRECT Trial: Examining Metformin’s effects on DR incidence over five years in type 2 diabetes patients¹.
• ePREDICE Study: Assessing Metformin’s role in preventing microvascular complications, including DR, in prediabetic individuals over two years.
• Phase II Trials: Exploring Metformin’s impact on geographic atrophy in AMD patients and visual field loss in glaucoma.

These studies aim to provide definitive evidence and optimal dosing strategies for Metformin in eye health.

Safety and Considerations

Before using Metformin for eye diseases, consider the following:

• Renal and Hepatic Function: Impaired kidney or liver function increases the risk of lactic acidosis.
• Gastrointestinal Tolerance: Side effects like nausea and diarrhea are usually mild and temporary.
• Drug Interactions: Metformin may interact with other medications; consult a healthcare provider.

Professional medical advice is crucial for safe and effective use.

Conclusion

Metformin emerges as a promising agent against various retinal diseases, supported by compelling evidence. Its anti-inflammatory, anti-angiogenic, and antioxidative mechanisms make it valuable for preserving vision and slowing disease progression. As clinical trials continue, Metformin may soon become integral in managing eye conditions, enhancing the quality of life for millions.

Interested in exploring Metformin for eye health? Consult with your ophthalmologist and endocrinologist to tailor a treatment plan to your needs.

About Us

At Canadian Insulin, we are dedicated to providing up-to-date health information and high-quality medications. Explore our range of products and let us support your journey to better eye health.